



Advances and Prospects in the Control of Biofilm-Related Fungal Infections by Natural Products

Guest Editor:

Prof. Dr. Melyssa Negri

Laboratory of Medical Mycology,
Department of Clinical Analysis
and Biomedicine, Universidade
Estadual de Maringá, Maringá,
Brazil

Deadline for manuscript
submissions:

closed (15 February 2024)

Message from the Guest Editor

Biofilm formation is an important virulence factor of fungi and contributes towards the resistance to host immune responses as well as to antifungal resistance and environmental stresses. Biofilm-related fungal infections are generally more severe than those caused by fungi alone, leading to increased antimicrobial resistance and prolonging the time required for host recovery. In addition, the available anti-biofilm therapeutic arsenal is limited, and the development of new drugs has been necessary. Therefore, the search for alternative drugs with low resistance rates and fewer side effects remains a major challenge. A considerable number of studies on medicinal plants and alternative compounds, However, further research on the effects and treatment on fungal biofilms is needed.

The main mission of this Special Issue will be to discover the advances and perspectives on the control and treatment of fungal biofilms by natural products. We believe that the contributions published in this issue will help us significantly expand our knowledge on alternative therapies to control fungal biofilms.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and
Molecular Bioscience, University
of Wollongong, Wollongong, NSW
2522, Australia

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPUS / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

Contact Us

Antibiotics Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibiotics
antibiotics@mdpi.com
[X@antibioticsmdpi](https://twitter.com/antibioticsmdpi)